Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sandoz s.p.a. - fludarabina - fludarabina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

teva italia s.r.l. - fludarabina - fludarabina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

fresenius kabi oncology plc - fludarabina - fludarabina

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

roche pharma (schweiz) ag - obinutuzumabum - concentrato per soluzione per infusione - obinutuzumabum 1000 mg, histidinum, histidini hydrochloridum monohydricum, trehalosum dihydricum, poloxamerum 188, aqua ad iniectabile q.s. ad solutionem pro 40 ml. - la leucemia linfatica cronica, linfoma follikuläres - biotechnologika

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

sanofi b.v. - fludarabina - fludarabina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

accord healthcare, s.l.u. - fludarabina - fludarabina

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

medac gesellschaft fur klinische spezialpraparate mbh - bendamustina - bendamustina

Unione Europea - italiano - EMA (European Medicines Agency)

astrazeneca ab - acalabrutinib - leucemia, linfocitica, cronica, b-cell - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.

Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

eugia pharma (malta) limited - bendamustina - bendamustina

Unione Europea - italiano - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - venetoclax - leucemia, linfocitica, cronica, b-cell - agenti antineoplastici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.